Neonatal and Infantile Immune Responses to Encapsulated Bacteria and Conjugate Vaccines by Klein Klouwenberg, Peter & Bont, Louis
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2008, Article ID 628963, 10 pages
doi:10.1155/2008/628963
ReviewArticle
Neonatal and Infantile Immune Responses to Encapsulated
Bacteria and Conjugate Vaccines
Peter Klein Klouwenberg and Louis Bont
Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Centre,
Room KE4.133.1, P.O. Box 85090, 3508 AB Utrecht, The Netherlands
Correspondence should be addressed to Louis Bont, l.bont@umcutrecht.nl
Received 22 March 2008; Revised 25 June 2008; Accepted 1 August 2008
Recommended by Michel Goldman
Encapsulated bacteria are responsible for the majority of mortality among neonates and infants. The major components on the
surface of these bacteria are polysaccharides which are important virulence factors. Immunity against these components protects
against disease. However, most of the polysaccharides are thymus-independent (TI)-2 antigens which induce an inadequate
immune response in neonates and infants. The mechanisms that are thought to play a role in the unresponsiveness of this age
group to TI-2 stimuli will be discussed. The lack of immune response may be overcome by conjugating the polysaccharides to
a carrier protein. This transforms bacterial polysaccharides from a TI-2 antigen into a thymus-dependent (TD) antigen, thereby
inducing an immune response and immunological memory in neonates and infants. Such conjugated vaccines have been shown
to be eﬀective against the most common causes of invasive disease caused by encapsulated bacteria in neonates and children. These
and several other approaches in current vaccine development will be discussed.
Copyright © 2008 P. Klein Klouwenberg and L. Bont. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Globally, more than 2.5 million infants die every year from
bacteremia, respiratory, and diarrhoeal diseases [1]. A lim-
ited number of viral and bacterial pathogens are responsible
for this burden of disease among neonates and infants. A
study by the WHO has identiﬁed that the most pathogenic
bacteria are encapsulated bacteria, such as Streptococcus
pneumoniae, Streptococcus pyogenes, Staphylococcus aureus,
Escherichia coli, Neisseria meningitidis,a n dHaemophilus
inﬂuenza [2]. The capsule around these pathogens is formed
by a polysaccharide coating. The immunologic advantage of
this coating is evasion of phagocyte killing, as the coating
blocks complement binding and opsonization. This can be
overcome by C-reactive protein (CRP) binding [3] and the
production of antibodies against the polysaccharide [4].
This immune response confers protection against disease.
However, especially the young [5], but also the elderly [6],
have a weak immunological response to these encapsulated
bacteria due to the thymus independent (TI) nature of these
bacteria.
The humoral immune response to antigens can be
divided into thymus-dependent (TD) and TI-responses
[7] (see Table 1). TD antigens consist of soluble proteins
or peptides and associate with major histocompatibility
complex (MHC) molecules at the surface of an antigen
presentingcell(APC),thusallowingtheAPCtointeractwith
CD4+ T cells. In contrast to TD antigens, TI antigens do not
requireT-cellstoinduceanimmune response[8]. Therefore,
TI antigens do not or poorly induce an immunological
memory. The antibodies that are produced are primarily
of the IgM isotype and in lesser quantities IgG2 [7]. The
TI antigens are further divided into two categories based
on their interaction with B cells: type 1 (TI-1) and type
2 (TI-2) antigens [7–9]. TI-1 antigens induce proliferation
and diﬀerentiation of B lymphocytes and induce immune
responses in adults, but also in neonates [5, 10]. TI-
2 antigens on the other hand induce a limited immune
response in children below two years of age, but older
children and adults react to TI-2 antigens with the formation
of suﬃcient antibody production by activated B-cells. TI-
1 antigens include lipopolysaccharides, which is part of2 Clinical and Developmental Immunology
Table 1: Characteristics of thymus-dependent and thymus-independent antigens
Characteristics Thymus-dependent Thymus-independent type 1 Thymus-independent type 2
TH-cell activation ++ −−
IgM-IgG switch +, IgG1, IgG3 +/−, IgM, IgG2 (low quantities) −,I g M
Booster response ++ −
Immune response in neonates High (but lower than in adults) Intermediate Low
Development of antibody responses At birth 3–18 m 24 m
Examples Protein antigens LPS PS
the Gram-negative bacteria cell wall [6]. Therefore, immune
responses to Gram-negative bacteria are relatively suﬃcient
in neonates and infants compared to encapsulated bacteria,
but still below levels of those of adults [10, 11]. TI-2 antigens
are bacterial polysaccharides from encapsulated bacteria
such as most S. pneumonia serotypes, N. meningitidis,a n d
H. inﬂuenza [12]. Infection with these bacteria results in a
reduced immunological response in neonates and therefore
they are at risk [5]. The polysaccharides of some other
bacteria such as S. pneumoniae serotype 3, however, are not
classiﬁed as TI-2 antigens.
The global use of eﬀective vaccines directed against
encapsulated polysaccharide pathogens would reduce the
morbidity and mortality among newborns and infants
signiﬁcantly [13]. In poor resource countries medical care
strikingly decreases after the ﬁrst year of life, necessitating
the development of eﬀective infant immunization programs
[14]. The challenge for early life immunization is to
induce sustained protection circumventing immaturity of
the immune system to TI-2 antigens [15]. Neonatal and
infantile antibody responses tovaccinesareofshortduration
and decline rapidly within a few months [16]. This may be
associated with a resurgence of vulnerability to infection,
requiringtheadministrationofrepeatedvaccinationsalready
in the second year of life. A better understanding of the
neonatal response to polysaccharide antigens may lead to the
development of improved vaccines. This review will explore
the neonatal immune response on polysaccharide antigens
and on polysaccharide protein conjugates. Furthermore, the
eﬃcacy and drawbacks of the three main polysaccharide-
conjugate vaccines will be discussed.
2. NEONATAL IMMUNE RESPONSES
TO POLYSACCHARIDES
There is a marked limitation in neonatal and infantile
antibody responses to most, but not all, bacterial capsular
polysaccharides [5]. The mechanisms that are thought to
account for the partial unresponsiveness of neonates to TI-
2 stimuli will be reviewed in the next paragraphs.
2.1. Bcellimmaturity
Polysaccharide antigens localize preferentially to the mar-
ginal-zone (MZ) B cells, found only in the spleen. These
B cells are present in low numbers at birth and the
development is deﬁcient in neonates [17]. MZ B cells with
adult features appear after 2 years of life and coincide with
the ability to induce an immune response to polysaccharides.
Children under two years of age have a quantitative defect
in IgG2 and IgG4 isotypes [18]. Although other isotypes
reach adult levels by two to three years of age, IgG2
appears much later in development, and adult levels of
this subclass are not reached until 5–10 years of age [19].
As the IgG2 isotype is considered as the most eﬀective
immunoglobulin against some polysaccharides [20], the
susceptibility of neonates and infants might be due to
the defect in immunoglobulin production. Furthermore, a
dysfunctional spleen or splenectomy increases the risk of
infection by encapsulated bacteria, such as S. pneumoniae
and requires antibiotic prophylaxis [21] or vaccination
[22].
The possibility that B cell immaturity in the MZ B cells
might cause the reduced TI-2 antigen response was ﬁrst
observed in mice by Mosier et al. [23]. With the develop-
ment of the murine immune system, B cells change from
IgMhiIgDlo to IgMloIgDhi and the response to TI-2 antigens
coincided with the appearance of IgD, which takes about one
to two weeks in mice [24]. Furthermore, it was shown that
mice with an X-linked immune deﬁciency (CBA/N mice)
resulting in B cells that phenotypically resemble neonatal B-
cells are unable to respond to TI-2 antigens [23]. The murine
MZ expresses the speciﬁc intercellular adhesion molecule-
grabbing nonintegrin receptor 1 (SIGNR1) which plays a
relevant role in the immune response against encapsulated
bacteria [25, 26], but its human homologue has not yet been
found.
2.2. CD21andcomplement
The immune response to polysaccharides is initiated when
polysaccharides activate complement factor C3d via the
alternative pathway [27]. The resulting polysaccharide-
complement complex subsequently localizes in MZ B cells
expressingCD21(complementreceptor2)[27,28].Neonatal
and infantile B cells have low expression of CD21 which
explains the inadequate response to polysaccharides [17,
28]. Interestingly, the increase of CD21 that occurs during
development coincides with the response to polysaccharides.
Furthermore, neonates have relatively low levels of comple-
ment [29]. Therefore, in early age, CD21 cannot bind the
polysaccharide-C3d complex suﬃciently and antibodies are
not produced. Conjugate vaccines, however, are complement
independent and induce an antibody response in neonates
and young children, which implies that MZ B cells are not
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In a murine model, Breukels et al. [30] showed that
polysaccharide-conjugates localize in the splenic MZ of
neonatal mice without obvious relation to MZ B cells.
Furthermore, it was shown in adult mice that the antibody
response to polysaccharides is absent after cobra venom
factor (CVF) treatment, which depletes complement.
2.3. Tlymphocyteandcytokinedefects
Inspiteoftheirname,inmiceTI-antigensneedtheassistance
of unspeciﬁc T-cells and cytokines [31]. In neonatal mice
these signals are absent or diminished and B cells activated
by TI-antigens do therefore not diﬀerentiate. Neonatal
accessory cells are deﬁcient in interleukin (IL)-1 and tumor
necrosis factor (TNF)-α, which are important for TI-2
responses [32, 33]. Supplementation of a mouse model
with these cytokines enabled neonatal B cells to clonally
expand and diﬀerentiate [6, 32]. The reduced IL-1 and -6
production in neonatal mice by macrophages seems to
be related to a decreased level of several TLR’s (TLR2,
TLR4) [34, 35]. Also the increased activity of p38 MAPK, a
mitogen-activated protein kinase that is involved in the TLR
intracellularsignalingpathway,seemstoplayapivotalrolein
the unique cytokine phenotype of the neonatal macrophages
[35]. The identity of T cells involved in antibody responses
to TI-2 antigens is still unknown. Kobrynski et al. [31]
measured IgG antibody production after immunization with
pneumococcal polysaccharides in mice with disruptions in
selected genes of the T cell pathway. Nonclassical MHC class
I-like CD1 molecules and a subset of MHC class I-dependent
CD8+ cells were found to be essential for antibody responses
to TI-2 polysaccharides.
2.4. Otherhypotheses
Several other explanations have been proposed and rejected.
A speciﬁc B cell subset, B-1, is thought to be important for
TI-2 responses since certain TI-2 speciﬁcities are found in
this subset. However, neonates have concentrations of B1-
cells comparable to adults and it seems unlikely that this is
the cause of reduced TI-2 responses [6]. Another view was
based on the increased susceptibility of immature B cells
to tolerance induction [36]. Lastly, it was thought that TI-
2 antigens cause a relative increase in suppressor T cells
compared to ampliﬁer T cells in a murine model, which
reﬂects an imbalance between Th1 and Th2, in favor of Th1
cells. However, this is unsatisfactory since the current data
suggest a Th1 deﬁciency in neonates [6].
3. POLYSACCHARIDE CONJUGATE VACCINES
The impaired neonatal and infantile immune response to
polysaccharide vaccines can be circumvented by conjugating
the polysaccharide to a protein carrier [37–39], based on
the old dogma that haptens when attached to a protein
carrier can induce an immune response. The mechanism
by which a polysaccharide-protein conjugate vaccine acts
is depicted in Figure 1.T o d a y ,a l lc u r r e n tp o l y s a c c h a r i d e
vaccines registered for children below age two are conjugated
vaccines. Conjugates transform bacterial polysaccharides
fromaTI-2antigeninto aTD-antigenandtherebyinducean
immune response and immunological memory in neonates
[40], however not to the extend as in adults [4]. Several
factors which are related especially to immunizations might
contribute to a suboptimal response to conjugate vaccines.
Firstly, the route of immunization determines the recall
response to polysaccharides in mice that have been vacci-
nated with a conjugate as neonates [41]. Secondly, the choice
of type of protein conjugate is important and determines the
amount of IgG antibody response [41]. Lastly, in neonatal
mice there is a Th-2 skew which leads to a predominantly
IgG1 response and impaired IgG2a antibody formation [4],
the latter thought to be more protective against encapsulated
bacteria [6].
3.1. HaemophilusinﬂuenzaBconjugatevaccine
Several Haemophilus inﬂuenza B (HiB) conjugate vaccines
were introduced in the early 1990s. The reported eﬃcacy
against meningitis and epiglottitis ranged from 94% in
children of 2-3 years of age to 99% for infants below 1
year of age [42]. In Brazil, the conjugate vaccine led to a
decrease in HiB meningitis 2.39 to 0.06 cases per 100000
population (98%) overall, and from 60.9 to 3.1 cases per
100000 population (95%) in children <1y e a ro fa g e ,ﬁ v e
yearsaftertheintroductionofthevaccine[43].Furthermore,
the HiB conjugate vaccines reduced carriage of HiB [44]a n d
probably led to lower transmission rates to children who
lacked protective antibodies.
3.2. Neisseriameningitidisconjugatevaccine
Puriﬁed polysaccharides from N. menigitidis serogroups A,
C, W135, and Y are available vaccine products and elicit
antibody responses with no memory function, with the
exception of serogroup A polysaccharide which induces
a marginal antibody response also in infants [45]. The
serogroup C polysaccharide is not immunogenic in children
below 2 years of age, and development of antibody titers is
slow [46]. Conjugates have been developed using the same
principles as for HiB. The type A and C conjugate vaccines
aresafeandwelltoleratedininfantsandyoungchildren[47].
In Spain, the meningococcal C vaccine (MCC) was eﬀective
in 98% of infants vaccinated at two, four, and six months
of age and 99% in those vaccinated after seven months of
age [48]. However, the vaccine eﬀectiveness fell after the ﬁrst
year, especially in those vaccinated as infants. In England,
the estimated eﬀectiveness was 66% in infants vaccinated
at two, three, and four months of age and 83% in those
vaccinated after seven months of age [16]. It fell to low levels
after one year in those vaccinated in the ﬁrst year of life. A
vaccine against type B (MenB), which is a common cause
of meningococcal disease, is presently unavailable [49, 50].
However, unpublished data provide a source of optimism
to develop a safe and eﬀective containing recombinant
outer membrane surface proteins of MenB vaccine from
the N. meningitidis strain NZ98/254. This investigational
vaccine against MenB induced protective immune responses4 Clinical and Developmental Immunology
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Figure 1: Schematic diagram of mechanism of action of PS and PS-protein conjugate vaccines. (a) Polysaccharide vaccines stimulate
marginal zone B-cells which will proliferate in loco and diﬀerentiate into short-living plasma cells, which are responsible for the rapid
release of low-aﬃnity antibodies and thus ﬁrst-line defence against the pathogen; (b) conjugate vaccines stimulate B-blasts that will migrate
into the germinal centre, where they proliferate, undergo somatic hypermutations and isotype class switch, and diﬀerentiate into either
long-living plasma cells (that produce high-aﬃnity antibodies) and memory B cells. Abbreviations: CD40L (CD40 ligand), GC (germinal
centre), MZ (marginal zone), DC (dendritic cell), MZ DC (marginal zone dendritic cell).
against 3 strains after the third dose (Miller et al. abstract
133, Annual Meeting of the European Society of Paediatric
Infectious Diseases (ESPID, 2008)). Results from Phase 3
RCTs are expected during the coming years.
3.3. Streptococcuspneumoniaeconjugatevaccine
Diseases caused by pneumococci include pneumonia,
meningitis, otitis media, sinusitis, and bronchitis. Pneu-
mococcal vaccines that are eﬀective in infants have been
welcomed as resistance against growing commonly used
antibiotics [51]. An unconjugated 23-valent vaccine is reg-
istered for children over two years of age but is ineﬀective
in younger children [52]. A 7-valent polysaccharide-protein
conjugate vaccine (PCV-7) has been introduced for use
in children below the age of 2 years. Serotypes included
in PCV-7 cover 65–80% of serotypes that cause invasive
pneumococcalinfections[53].Otherconjugatevaccineswith
wider serotype coverage, including a 10-valent vaccine and a
13-valent vaccine, are in the late stage of development [54,
55]. A 94% decrease in vaccine type invasive pneumococcal
disease in children with a coverage rate of just 68% was
reported [56]. The number of all-cause pneumonia admis-
sion rates has declined by 39% for children younger than
two years in the USA from 2000–2004 [57] and admissions
due to pneumococcal meningitis were reduced by 66% in
the same period [58]. A signiﬁcant decrease was also seen
in the unvaccinated groups as a result of herd immunity
due to decreased transmission from vaccinated children to
unvaccinated contacts [56]. The protective eﬃcacy against
acute otitis media however has been relatively modest. In a
Finnishstudy,theeﬃcacyagainstconﬁrmedotitismediawas
34% and the overall eﬃcacy against otitis media regardless of
cause was only 6% [59].
3.4. Otherconjugatevaccines
Several other polysaccharide pathogens are under inves-
tigation. Group B streptococci are the major cause of
meningitis and sepsis in neonates. In animal studies, group
B streptococcal conjugate vaccines have shown to be able to
induceprotectiveantibodies[60].Similarattemptshavebeen
made to develop immunogenic and safe vaccines against the
Vi polysaccharide of S. typhi [61] and polysaccharides and
LPS of E. coli [62]a sw e l la sS. aureus [63].
4. DRAWBACKS OF CONJUGATE VACCINES
As described above, polysaccharide-conjugate vaccines are
eﬀective in children under the age of two years. However,P. Klein Klouwenberg and L. Bont 5
conjugate vaccines are only available for H. inﬂuenza type
B, some meningococcal subtypes, and recently for a limited
number of subtypes of S. pneumoniae. Vaccine failure and
rise of nonserotype bacteria have been noticed and require
continuous attention [64]. There is evidence that coadmin-
istration with other vaccines may impair eﬀectiveness of the
vaccinations [65]. Finally, conjugate vaccines are expensive,
which does not allow for global use of these vaccines [53].
4.1. HaemophilusinﬂuenzaBconjugatevaccine
A decade after its introduction in the UK, the ﬁrst conjugate
vaccine, HiB, became less eﬀective and vaccine failures
were seen [66]. Two explanations have been given for this
eﬀect. First, after early age immunization antibody levels are
suﬃcient for protection but drop over the following years,
sometimes to levels that are not considered protective. This
was explained by a reduction in either the number or the
quality of memory B cells induced by immunization or a
loss of avidity in matured B cells prior to disease onset
following defective priming [67]. The low titers observed in
the UK may have been exacerbated by the loss of “natural
boosting”associatedwithareductionincarriage.Reboosting
might be the solution [67]. The other important factor
contributing to the reduced immune response to HiB-
conjugate-vaccine is the current coadministration with other
vaccines.ReducedantibodyresponsestoHiBconjugateshave
been documented using acellular pertussis/HiB [65], DTaP-
HiB [68], and MCC/HiB combinations [69], but not in
other studies [70, 71]. The impaired immune responses were
increased by accelerated immunization schedules such as
that in the UK [72]. The precise immunological mechanism
responsible for the excess of vaccine failures following the
combination vaccine is not known.
4.2. Neisseriameningitidisconjugatevaccine
The meningococcal serogroup B polysaccharide is poorly
immunogenic in man [73]. The development of an eﬀective
vaccine against N. meningitidis serogroup B is complicated
by the inability of this polysaccharide to induce a signiﬁcant
antibody response [73], even when conjugated to a carrier
protein [74]. However, unpublished data show promising
results (Miller et al. abstract 133, Annual Meeting of the
European Society of Paediatric Infectious Diseases (ESPID,
2008)). In Spain and the UK, the MCC vaccine eﬀectiveness
fell after the ﬁrst year, especially in those vaccinated as
infants [16, 48]. These data suggest that the protection given
by MCC vaccine may be age dependent and that children
vaccinated at an older age may have greater and longer-
lasting protection than those vaccinated as infants. This
suggests that protection may be more reliant on circulating
antibodies at the time of exposure than on the ability to
mountaboosterresponse[75].Arecentstudyfoundthatthe
immune response and length of protection were dependent
on the formation of a large germinal center one month after
primary immunization with the MCC vaccine [76]. One
third of infants in this study produced a very low number
of memory B cells after the initial immunization and did
not maintain protective antibody levels by one year of age.
In these children, the germinal center was underdeveloped.
Understanding of the factors that determine the production
of these germinal centers could lead to improved conjugate
vaccines. Until then, booster doses of MCC may be required
in order to extend the duration of protection oﬀered by the
vaccine.
4.3. Streptococcuspneumoniaeconjugatevaccine
A major drawback of pneumococcal conjugate vaccines is
that the serotypes included in PCV-7 cover only 65–80% of
serotypes that cause invasive pneumococcal infections [53].
Eﬀortstoincludemoresubtypesinaconjugatevaccineprove
to be very complicated and costly. Furthermore, it has been
shown that combination of PCV-7 with other vaccines can
lead to reduced immune responses. The response to hepatitis
B vaccine was nonsigniﬁcantly reduced with concomitant
administration with PCV-7 [77]. Another problem is that
the PCV-7 vaccine replaces disease by nonvaccine serotypes
especially 19A [78] and 16F [59]. A recent study in Alaska,
where routine vaccination in children has started in 1999–
2000, showed an increase in invasive pneumococcal disease
rate caused by nonvaccine serotypes of 140% compared with
the prevaccine period [64]. In the ﬁrst three years after
introduction of the PCV-7 vaccine, there was a 96% decrease
inheptavalentvaccineserotypedisease.Thisledtoadecrease
in overall invasive pneumococcal disease of 67% in Alaskan
children younger than 2 years (from 403.2 per 100000 in
1995–2000 to 134.3 per 100000 per year in 2001–2003) but
to an 82% increase in invasive disease in the following years
to 244.6/100000. Serotype 19A accounted for 28% of inva-
sive pneumococcal disease among Alaska children younger
than 2 years during 2004–2006. There was no signiﬁcant
increase in disease due to nonvaccine serotypes in nonnative
Alaskan children younger than 2 years [64]. This emphasizes
the importance of continuing surveillance and development
of expanded valency vaccines. The question remains whether
this serotype shift leads to increased morbidity and mortality
rates as these nonvaccine types are typically less pathogenic.
Other limitations are a modest eﬀect on nasopharyngeal
colonization [79], cost (US$ 32000–166000 per life-year
saved) [53], and diﬃculties in production that have led to
shortages.
5. NEW DEVELOPMENTS
The currently registered conjugated polysaccharide vaccines
have been developed based upon the principle that CD4 T
cell recruitment is necessary for the activation of the infant
Bc e l li m m u n er e s p o n s e[ 8]. The underlying thought was to
promote a transformation of the neonatal immune response
fromaTIonetoaTDonebyconjugatingthepolysaccharides
to immunogenic carrier proteins. The neonatal immune
response to TD-antigens has been shown to be better than
the response to TI-2 antigens but did not reach levels seen
in healthy adults [4]. One of the most important factors
determining the neonatal immune response to conjugate
vaccines seems to the type of carrier protein used in the6 Clinical and Developmental Immunology
conjugate [4]. The carrier determines the level of induction
of speciﬁc T cells and therefore the levels of polysaccha-
ride antibodies and hence the protective eﬀect gained by
administration of the conjugate vaccine. The optimal carrier
mightbediﬀerentfordiﬀerentpneumococcalserotypes[80].
In one study pneumococcal polysaccharide conjugated to a
diphtheria carrier was more eﬃcient in inducing a mucosal
response, while tetanus conjugate resulted in improved
systemicresponses[81].Anotherstudyshowedthatatetanus
conjugate resulted in a better serotype 4 response, while a
diphtheria conjugate evoked a better response to types 3, 9V,
and 14 [82].
The addition of adjuvants to conjugate vaccines could
potentially reduce the number of doses needed to estab-
lish protective immunity and thereby provides protective
immunity within a shorter time period and at a reduced
cost. Adjuvants also lead to more consistent induction of
responses to various polysaccharide serotypes [83]. Toll-
like receptor (TLR) ligands have been considered as vaccine
adjuvants [84, 85], such as CpG containing oligodeoxynu-
cleotides [86]. Peptide p458 is a peptide derived from
the human or mouse 60-kDa heat shock protein (hsp60)
and stimulates TLR4 [84]. Conjugated to pneumococcal
polysaccharide type 4 it could induce protection in mice
againstasupralethalS.pneumoniaechallenge.Protectionwas
associatedwithpolysaccharidetype4-speciﬁcIgGantibodies
in most but not in all the mice, a T cell response to the
p458 carrier and long-term memory. Vaccines composed of
p458 conjugated to the polysaccharides of Salmonella [87],
or meningococcus B and C [88] were also immunogenic in
mice, even when injected without an added adjuvant. Other
TLR agonists that stimulate TLR8, such as R-848 (TLR7/8),
the imidazoquinoline congeners 3M-003 (TLR7/8) and 3M-
0 0 2( T L R 8 ) ,a sw e l la ss i n g l e - s t r a n d e dv i r a lR N A s( T L R 8 ) ,
also induce a strong immune response in neonates and
infants by stimulating p38 MAPK phosphorylation [85].
Furthermore, LT-K63, a nontoxic mutant of E. coli heat-
labile enterotoxin [89], when administered concomitantly
with a conjugated pneumococcal polysaccharide serotype
1, enhanced IgG responses in infant mice compared to
conjugated polysaccharide alone [89]. A second dose of
conjugated pneumococcal polysaccharide resulted in very
high IgG responses and signiﬁcantly improved protection
against lethal pneumococcal infections in this animal model.
Similar results were obtained with an MCC vaccine [90].
Furthermore, the route of administration is also shown
to be an important determinant in eliciting protective
immunity in neonates [4, 89]. Intranasal immunization with
conjugated polysaccharides [89, 91]s e e m e dt ob ee ﬀective
both in infantile and neonatal mice. A single intranasal dose
of conjugate vaccine elicited a suﬃcient high IgG response
to protect neonatal mice against pneumococcal infections,
whereas subcutaneous administration required two doses to
induce complete protection. The increased eﬃciency could
be explained by the additional induction of a salivary IgA
response after intranasal administration. However, antibody
responses and protective eﬃcacy remained signiﬁcantly
lower than in adult mice [89]. One of the main reasons for
this seems to be the lack of eﬀective adjuvants [92].
Another strategy in early stage of development is the use
of surface proteins. An example is the Pneumococcal surface
protein A (PspA) that is a cell-wall-associated surfaceprotein
[93]. It is known to play a major role in the pneumococcal
virulence; it binds human lactoferrin and interferes with
complementdepositiononthebacterialsurface.Itisthought
thatitmightresultinbetterimmuneresponsesininfantsand
neonates. The antibody response to PspA has been studied in
children [93, 94]. The pneumococcal surface antigen protein
A (PsaA) is currently explored as a vaccine candidate. It is
structurally conserved [95] and plays a role in adherence to
host mucosae [96] .U n t i ln o w ,h o w e v e r ,i th a sn o tb e e nu s e d
as vaccine antigen in humans.
Another potential vaccine strategy is the development
of peptides that mimic polysaccharide antigens [97]. The
main advantage of using peptides over polysaccharides is
that peptides induce a TD antigen response as they are
processed by APC’s and presented to T cells. A drawback
of the use of peptides in vaccines is their poor chemical
stability and subsequently lower immunogenicity in vivo.
DNA-based vaccines are another potential approach as they
are more stable but were initially not considered a viable
option for pathogens coated with polysaccharides since
carbohydrate antigens are secondary gene products [97].
However, it was recently shown that a DNAvaccine could
induce an IgG2a isotype response against a polysaccharide
antigen [98]. Other possible advantages of DNA-vaccines
are the relatively straightforward and cheaper production
techniques compared to conjugate vaccines.
6. CONCLUSION
Neonatalimmuneresponsestopolysaccharidepathogensare
very weak. Therefore, neonates and young children are at risk
for invasive infections with S. pneumococcus, N. meningitidis,
and H. inﬂuenza. An important percentage of deaths among
neonates are caused by these bacteria. The eﬃcacy of the
currently used conjugate vaccines is already very high in the
population most at risk, but worldwide utilization of these
vaccines is hampered by high production costs. Knowledge
about neonatal immunological responses to polysaccharide
antigens may open the way for the application of newly
designed conjugated vaccines or vaccines based on other
principles in this patient group. Currently, several strategies
are being explored to get insight into the mechanisms
underlying the limitations of infant responses and to thereby
improve neonatal vaccination eﬃciency.
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